A R ANDOMIZED C ONTROLLED T RIAL OF A P ACLITAXEL -E LUTING S TENT V ERSUS A S IMILAR B ARE -M ETAL S TENT IN S APHENOUS V EIN G RAFT L ESIONS Journal.

Slides:



Advertisements
Similar presentations
Paclitaxel-eluting Stents vs Brachytherapy for In-stent Restenosis (TAXUS V ISR) Trial Presented at The American College of Cardiology Scientific Session.
Advertisements

Is Direct Stenting Superior to Stenting with Predilation in Patients Treated with Percutaneous Coronary Intervention? Results from a Meta-Analysis of 24.
Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE) Trial Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE)
The AiMI Trial Arshad Ali, MD, David Cox, MD, Nabil Dib, MD, Bruce Brodie, MD, Daniel Berman, MD, Navin Gupta, MD, Kevin Browne, MD, Robert Iwaoka, MD,
Arterial Revascularization Therapies Part II: a non- randomized comparison of contemporary PCI and coronary artery bypass grafting (CABG) in patients with.
The REALITY Study Results. REALITY Study Design The REALITY Study : Prospective randomized clinical trial to evaluate the safety and efficacy of CYPHER®
PLATINUM A Prospective, Randomized, Investigation of a Novel Platinum Chromium Everolimus-Eluting Coronary Stent: The PLATINUM Trial Objective To evaluate.
Rapamycin- and Paclitaxel-Eluting Stents With Identical Biodegradable Polymeric Coating and Design Trial Presented at The American College of Cardiology.
Treatment of In-Stent Restenosis by Paclitaxel Coated PTCA Balloons Presented at The American Heart Association Scientific Session 2006 Presented by Dr.
SIROLIMUS-ELUTING STENTS EFFECTIVELY INHIBIT NEOINTIMAL PROLIFERATION AS COMPARED TO BARE METAL STENTS IN DISEASED SAPHENOUS VEIN GRAFTS: 6-month IVUS.
A Randomized Comparison of Everolimus-­ Eluting Absorb Bioresorbable Vascular Scaffolds vs. Everolimus-Eluting Metallic Stents: One-Year Angiographic and.
TAXUS ATLAS Trial Presented at The EuroPCR meeting Paris, France May 2006 Presented by Dr. Mark Turco TAXUS ATLAS 9-Month Results: Evaluation of TAXUS.
LONG-TERM OUTCOMES OF PERCUTANEOUS CORONARY INTERVENTION FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE: INITIAL CLINICAL EXPERIENCE. Graidis Ch. 1,
Paclitaxel Eluting Stent Versus Conventional Stent in ST-segment Elevation Myocardial Infarction (PASSION) Trial Presented at The American College of Cardiology.
Slow-rate release polymer-based paclitaxel- eluting stent compared with bare stent in patients with single complex coronary lesions TAXUS V Presented at.
A Prospective, Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients TReated with Endothelial Progenitor Cell CapTuring Stents for De Novo.
LONG-TERM CLINICAL OUTCOMES AFTER REPEAT DRUG-ELUTING STENT IMPLANTATION FOR IN DRUG-ELUTING STENT RESTENOSIS. C. Graidis, D. Dimitriadis, A. Ntatsios,
RESOLUTE US One-Year Clinical Outcomes from the Pivotal Multicenter RESOLUTE US Study Objective To evaluate the clinical effectiveness of the Resolute.
Prospective, Randomized Trial of Paclitaxel-Eluting Balloon versus Paclitaxel-Eluting Stent versus Balloon Angioplasty for Treatment of Coronary Restenosis.
ISAR-CABG Objective To compare the efficacy of DES with BMS in a randomized trial powered for clinical events Sample 610 patients with de novo SVG lesions.
A Prospective, Randomized Trial of a Paclitaxel coated Balloon vs. uncoated Balloon Angioplasty in Patients with Drug- Eluting Stent Restenosis PEPCAD-DES.
The GREAT Trial. The Grampian Region Early Anistreplase Trial Reference Zahringer M, Sapoval M, Pattynama PM, et al. Sirolimus-eluting versus bare-metal.
Date of download: 6/25/2016 Copyright © The American College of Cardiology. All rights reserved. From: Implantation of a Drug-Eluting Stent With a Different.
Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Paradigm shifts in cardiovascular medicine J Am.
Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Clinical restenosis after coronary stenting: perspectives.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Fractional Flow Reserve Versus Angiography for Guiding.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: A Meta-Analysis of 16 Randomized Trials of Sirolimus-Eluting.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Randomized Trial of Paclitaxel- Versus Sirolimus-Eluting.
Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at The American College.
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Relationship between heparin anticoagulation and.
Date of download: 7/10/2016 Copyright © The American College of Cardiology. All rights reserved. From: Impact of Coronary Anatomy and Stenting Technique.
From: Sustained Safety and Effectiveness of Paclitaxel-Eluting Stents for Femoropopliteal Lesions: 2-Year Follow-Up From the Zilver PTX Randomized and Single-Arm.
Date of download: 9/19/2016 Copyright © The American College of Cardiology. All rights reserved. From: Characteristics and Long-Term Outcomes of Percutaneous.
Date of download: 9/19/2016 Copyright © The American College of Cardiology. All rights reserved. From: Paclitaxel-Coated Balloon Angioplasty Versus Drug-Eluting.
The American College of Cardiology Presented by Dr. Nikolaus Marx
DCB for In-Stent Restenosis: Is It Superior to DES?
insights from a meta-analysis of
NORSTENT Trial design: Patients with obstructive coronary artery disease were randomized to a drug-eluting stent (DES) (n = 4,504) versus a bare-metal.
Robert A. Guyton, MD  The Annals of Thoracic Surgery 
Volume 54, Issue 1, Pages (August 2009)
Median target vessel revascularization rates per 1000 patient-years of follow-up with bare metal stents (BMS) and first- and second-generation drug-eluting.
LONG-DES II Trial Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary.
TAXUS IV Trial Slow-rate release polymer-based paclitaxel-eluting stent compared with bare stent in patients with single de novo coronary lesions Presented.
The Role of Interventional Treatment for The Failing Grafts
Stenting of Coronary Arteries in Non Stress/Benestent Disease
Impact of endoscopic versus open saphenous vein harvest technique on late coronary artery bypass grafting patient outcomes in the ROOBY (Randomized On/Off.
TAXUS II and IV: two-year follow-up
Robert A. Guyton, MD  The Annals of Thoracic Surgery 
The American College of Cardiology Presented by Dr. Maurits T. Dirksen
American College of Cardiology Presented by Dr. Stephan Windecker
European Society of Cardiology 2003
REALITY: 8 month results
TUXEDO–India Trial design: Patients with type 2 diabetes mellitus (DM2) and coronary artery disease undergoing PCI were randomized to receive Taxus Element.
ENDEAVOR IV: 5 Year Final Outcomes
Presented at ACC 2003 Late Breaking Clinical Trials
The American College of Cardiology Presented by Dr. Raimund Erbel
Large-Scale Registry Examining Safety and Effectiveness of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease Western.
SIRIUS: A U.S. Multicenter, Randomized, Double-Blind Study of the SIRolImUS-Eluting Stent in De Novo Native Coronary Lesions Presented at TCT 2002.
Main branch restenosis at 1 year
(p = 0.32 for noninferiority)
Drug-eluting stents for in-stent restenosis
Impact of previous coronary artery bypass surgery on clinical outcome after percutaneous interventions with second generation drug-eluting stents in TWENTE.
Total occlusion and string sign of radial artery versus saphenous vein graft conduits: An updated meta-analysis  Hisato Takagi, MD, PhD, Masafumi Matsui,
Martin B. Leon, David R. Holmes, Dean J. Kereiakes, Jeffrey J
Maintenance of Long-Term Clinical Benefit with
The American College of Cardiology Presented by Dr. Nikolaus Marx
Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial
American College of Cardiology Presented by Dr. Adnan Kastrati
The American College of Cardiology Presented by Dr. A. Abazid
TYPHOON Trial Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at.
Presentation transcript:

A R ANDOMIZED C ONTROLLED T RIAL OF A P ACLITAXEL -E LUTING S TENT V ERSUS A S IMILAR B ARE -M ETAL S TENT IN S APHENOUS V EIN G RAFT L ESIONS Journal of the American College of Cardiology Vol. 53, No. 11, 2009 R3 Kyu Seong Lim

B ACKGROUND There are conflicting and mostly retrospective data on outcomes after drug-eluting stent implantation in SVGs. Multicenter, randomized SOS (Stenting Of Saphenous Vein Grafts) trial to compare the angiographic and clinical outcomes after implantation of a PES versus BMS in SVG lesions.

R ESULT

D ISCUSSION Small number of patients enrolled The losses to angiographic follow-up All patients enrolled were male Although all repeat revascularizations were driven by clinical symptoms, the protocol- required angiographic follow-up might have increased rates of repeat coronary revascularizations in both study groups and particularly in the BMS arm The median follow up of SOS was 1.5years The outcomes seen with PES might not apply to other DES.

C ONCLUSION The use of PES in SVG lesions is associated with lower rates of angiographic restenosis and target vessel failure than BMS.